London 2014 Registration Visa Letters Programme Satellite Meetings Glaucoma Day 2014 Exhibition Hotel Booking Virtual Exhibition Star Alliance
london escrs

Course handouts are now available
Click here


Come to London

video-icon

WATCH to find out why


Site updates:

Programme Updates. Programme Overview and - Video Symposium on Challenging Cases now available.


Posters

Search Abstracts by author or title
(results will display both Free Papers & Poster)

Clinical experience with 0.05% cyclosporine A (Restasis) for management of dry eye after laser vision correction

Poster Details

First Author: T.Manoilo UKRAINE

Co Author(s):    G. Parkhomenko              

Abstract Details



Purpose:

To analyze the frequency of application 0.05% suspension of cyclosporine in patients after LVC

Setting:

'Noviy Zir' ophthalmosurgical clinic, Ukraine, Kyiv.

Methods:

: The retrospective analysis of 175 patients cards (350 eyes) was conducted after thin flap aspherical LASIK from January till May 2013. Standard ophthalmologic examination, Pentacam, basal secretion of tears were conducted in all patients before surgery. 60% of patients were soft contact lenses users, 28 % of patients had dry eye syndrome (1-2 stages) and had been taking artificial tears before LVC. Mean uncorrected VA (UCVA) was 0,05, mean best corrected VA (BCVA) was 0,9, Mean preoperative spherical equivalent was -5,19±1,91 D, mean preop pachymetry - 552.48±3.52 μm, mean corneal ablation depth - 52.48±3.52 μm. Test of basal tear secretion composed 9.03±2.53 mm. All surgeries went without complications.The LASIK flaps were created with the Carriaso-Pendular microkeratome and the ablation with the Schwind Amaris® 500 excimer laser (SCHWIND eye-tech-solution

Results:

Cyclosporine A 0,05% suspension (Restasis) had been prescribed month before the correction for 4% of patients. The change of refraction concomitant with taking the medicine was not found examining these patients. One month after LVC due to the strengthening of Dry eye symptoms (complaints, staining of cornea, minor fluctuation of refraction) Restasis was prescribed in 10% of cases. 8% of these patients had been taking Restasis for 4-6 months with an improvement of objective features and subjective symptoms of Dry eye. 2% of patients continue to take Restasis regularly or with monthly breaks. After 1, 3 and 6 months patients, who had been taking Restasis, had not had any deviation of planned postop refraction. Using Restasis on patients with straightening of Dry eye symptoms after LVC had improved UCVA on 1-2 Lines after 1-3 months after prescription. Basal secretion of these patients had improved on 35% in average, tearfilm time break increased on 25% after 3 month of taking the medicine.

Conclusions:

Application of Cyclosporine A 0,05% suspension (Restasis) allows to diminish Dry eye symptoms, which decrease functional indexes of patients after LVC, improve visual acuity. FINANCIAL INTEREST: NONE

Back to Poster listing